Celcuity CELC 深 沪
等待开盘 09-17 09:30:00 美东时间
53.07
-2.000
-3.63%
华盛通- 最 高55.91
- 今 开55.07
- 成交量 68.90万股
- 最 低 52.90
- 昨 收 55.07
- 总市值 22.52亿
- 52周最高 63.06
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 7.575
- 委 比 -31.01%
- 总股本 4242.67万
- 历史最高 63.06
- 量 比 0.72
- 振 幅 5.47%
- 历史最低 4.03
- 每 手 1
- 风险率 13.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Celcuity Expands Credit Facility to $500 Million
The latest update is out from Celcuity ( ($CELC) ). On September 9, 2025, Celcu...
09-10 20:17
Celcuity announces upsized loan facility of $500M
Celcuity (NASDAQ:CELC) said on Tuesday that it has entered into an amendment to its existing senior secured credit facility with an affiliate of Innovatus Capital Partners and Oxford Finance and its a...
09-10 04:19
Abivax’s 580% surge hands biotech hedge funds a rare 2025 win
Hedge funds specializing in biotech finally caught a break this summer, courtesy of a little-watched French drug developer, The Wall Street Journal reported on Saturday. Paris-based Abivax (NASDAQ:ABV...
08-31 20:30
Celcuity's NDA For Gedatolisib In HR+/HER2- Breast Cancer Accepted Into FDA's Real-Time Oncology Review Program
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the U.S. Food and Drug Administration ("FDA") agreed to accept its New Drug
08-28 04:14
Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program
Celcuity宣布FDA接受其针对HR+/HER2-晚期乳腺癌的药物gedatolisib的新药申请(NDA)并拟采用RTOR计划以加速审查。基于III期VIKTORIA-1试验中PIK3CA野生型队列的积极数据， Gedatolisib三联和双联疗法均显示出显著降低疾病进展或死亡风险，并在中位无进展生存期(PFS)上相比单独使用氟维司群有显著改善。
08-27 20:05
Analysts Conflicted on These Healthcare Names: Celcuity (CELC), UnitedHealth (UNH) and Assembly Biosciences (ASMB)
Analysts have been eager to weigh in on the Healthcare sector with new ratings ...
08-18 18:20
Needham Maintains Buy on Celcuity, Lowers Price Target to $70
Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $74 to $70.
08-15 18:05
Celcuity Q2 Adj. EPS $(0.93) Misses $(0.88) Estimate
Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.88) by 5.2 percent. This is a 60.34 percent decrease over losses of $(0.58) per share from the same
08-15 04:03
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
Insights into Celcuity's Upcoming Earnings
Celcuity (NASDAQ:CELC) is set to give its latest quarterly earnings report on T...
08-13 22:02
